Posted by Michael Wonder on 02 Aug 2022
Korea's first gene treatment for SMA Zolgensma gets insurance benefits
2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal muscular atrophy, on Monday with the registration of health insurance benefits.
This year, patients administering existing spinal muscular atrophy therapeutics will also temporarily be eligible for reimbursement if they are replaced with Zolgensma.
